191 related articles for article (PubMed ID: 6396765)
1. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
[No Abstract] [Full Text] [Related]
2. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Gelber RD
Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
[No Abstract] [Full Text] [Related]
3. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
Wallgren A; Baral E; Beling U; Carstensen J; Friberg S; Glas U; Kaigas M; Skoog L
Recent Results Cancer Res; 1984; 96():197-203. PubMed ID: 6396775
[No Abstract] [Full Text] [Related]
4. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
Tormey DC; Taylor SG; Gray R; Olson JE
Recent Results Cancer Res; 1984; 96():110-6. PubMed ID: 6396764
[No Abstract] [Full Text] [Related]
6. Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF; Arick CL
Cancer Invest; 2001; 19(7):706-22. PubMed ID: 11577812
[No Abstract] [Full Text] [Related]
7. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
Kaufmann M; Jonat W; Abel U
Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024
[No Abstract] [Full Text] [Related]
8. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS
Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861
[TBL] [Abstract][Full Text] [Related]
9. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
Jonat W; Kaufmann M; Abel U
Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028
[No Abstract] [Full Text] [Related]
10. Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients.
Goldhirsch A
Recent Results Cancer Res; 1984; 96():204-9. PubMed ID: 6549355
[No Abstract] [Full Text] [Related]
11. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptors. An update and application.
Hubay CA; Arafah B; Gordon NH; Guyton SP; Crowe JP
Surg Clin North Am; 1984 Dec; 64(6):1155-72. PubMed ID: 6393400
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
14. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
15. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.
Mauriac L; Durand M; Chauvergne J; Bonichon F; Avril A; Mage P; Dilhuydy MH; Le Treut A; Wafflart J; Marée D
Breast Cancer Res Treat; 1988 May; 11(2):179-86. PubMed ID: 3042053
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
Tormey C
Recent Results Cancer Res; 1984; 96():155-65. PubMed ID: 6396769
[No Abstract] [Full Text] [Related]
19. Adjuvant systemic therapy for operable breast cancer.
Stewart HJ
Br Med Bull; 1991 Apr; 47(2):343-56. PubMed ID: 1933218
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
